NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.364) was uploaded to the NHS England Website on Friday 23, May 2025.
The following changes have been introduced:
Selpercatinib (SEL3)
Selpercatinib as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) exhibiting a RET gene fusion and who have previously received immunotherapy and/or platinum-based chemotherapy where the following criteria have been met
Moved into routine commissioning - section B of list
Cabozantinib in combination with nivolumab (CABNIV1)
For use in treatment-naïve patients with intermediate or poor risk advanced renal cell carcinoma for whom combination treatment with either nivolumab plus ipilimumab or lenvatinib plus pembrolizumab would otherwise be suitable where the following criteria have been met
Treatment criteria (#9 and 11) updated
Nivolumab (NIV7)
Nivolumab for the adjuvant treatment newly diagnosed and completely resected stage III or completely resected stage IV malignant melanoma where the following criteria are met:
Treatment criteria (#5, 9 and 10) updated
Nivolumab (NIV8a)
Nivolumab monotherapy (with or without initial combination treatment with ipilimumab) for treating unresectable advanced malignant melanoma (form a): REGISTRATION OF START OF NIVOLUMAB MONOTHERAPY OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED NIVOLUMAB MONOTHERAPY (WITHOUT INITIAL COMBINATION WITH IPILIMUMAB) OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED NIVOLUMAB MONOTHERAPY AFTER INITIAL COMBINATION WITH IPILIMUMAB (clinicians starting patients on nivolumab plus ipilimumab combination treatment should only use this form after the ipilimumab part of the treatment has been completed). This form comes in 3 parts 1. The first part is for patients who are either scheduled to commence nivolumab monotherapy or who commenced and continue to receive nivolumab monotherapy or who continue to receive nivolumab monotherapy after initial combination treatment with ipilimumab. The second part of the form which must use the same unique Blueteq identifier for those benefitting patients who choose to electively discontinue nivolumab after or more years of treatment. 2. The second part (patient details will automatically entered) will only appear once the first part of the form is approved and should be completed at the time of elective discontinuation of nivolumab. The third part of the form which must use the same unique Blueteq identifier is for those patients registered as having electively and previously stopped nivolumab and whom there is disease progression for which the clinician wishes to re- commence nivolumab monotherapy. 3. The third part of the form (patient details will be automatically entered) will only appear once the second part of the form has been approved.
Treatment criteria (#9 and 11) updated
NA (NIV9)
NA
Treatment criteria (#9 and 11) updated
Nivolumab (NIV15)
For the treatment of adult patients with unresectable locally advanced or recurrent or metastatic squamous cell carcinoma the oesophagus previously treated with fluoropyrimidine and platinum-based combination chemotherapy where the following criteria have been met
Treatment criteria (#6 and 10) updated
Nivolumab (NIV19)
Nivolumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with high risk muscle invasive urothelial cancer with tumour cell PD-L1 expression of ≥1% and in whom adjuvant treatment with platinum-based chemotherapy is unsuitable where the following criteria have been met
Treatment criteria (#13 and 15) updated
Bevacizumab (BEV8)
The third line treatment of low grade gliomas of childhood where all the following criteria are met:
TA column updated